Background: Urinary collection over 24 h is a cornerstone in the care of patients with nephrolithiasis, obesity, hypertension, and chronic kidney disease (CKD). The completeness of 24-h urinary collection is assessed by urinary creatinine excretion, which reflects the muscle mass. Hence, it is of paramount importance to define expected values of daily urinary creatinine excretion to correctly interpret urinary collection. These references are available for the general population. We hypothesized that these reference values might not be applicable to individuals with obesity whose body composition is different from general population.
Objectives: Our objective was to define daily urinary creatinine excretion among population with obesity.
Methods: We conducted a monocentric, retrospective, observational study, including adult patients (≥18 y) admitted for measurement of glomerular filtration rate (GFR). Measurement of GFR requires timed urinary collections to calculate the urinary clearance of the tracer. We took advantage of timed urinary collection to calculate in-hospital urinary creatinine flow rate and to extrapolate it to 24 h (exUCreat for extrapolated 24-h creatinine excretion). We compared exUCreat between patients with obesity and healthy weight matched on height, age, sex, ethnic origin, 24-h urinary urea, and nonindexed GFR.
Results: We included 1091 patients [median age 56 y, interquartile range (44, 67); 62.7% males] with nondialysis CKD stages 1-5. Among them, 227 were obese. The exUCreat was higher among individuals with obesity than in healthy weight patients [13.9 (11.1, 17.3) compared with 11.0 (8.8, 13.9) mmol/24h; P < 0.01]. The 10th and 90th percentiles of exUCreat corrected for weight of individuals with obesity were significantly different from the 10th and 90th percentiles previously reported in the literature for the general population (P < 0.01).
Conclusion: Daily urinary creatinine excretion is significantly higher among individuals with obesity than in healthy weight population. We propose new standard reference for urinary creatinine excretion in individuals with obesity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajcnut.2024.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Urinary Biomarkers and Attainment of Cefepime Therapeutic Targets in Critically Ill Children.
Pediatr Infect Dis J
March 2025
From the Department of Pediatrics.
Background: Critically ill children are at risk for subtherapeutic antibiotic concentrations. The frequency of target attainment and risk factors for subtherapeutic concentrations of cefepime in children have not been extensively studied.
Methods: We performed an observational study in critically ill children receiving a new prescription of standard dosing of cefepime for suspected sepsis (≥2 systemic inflammatory response syndrome criteria within 48 hours of cefepime start).
Podocyte A20/TNFAIP3 Controls Glomerulonephritis Severity via the Regulation of Inflammatory Responses and Effects on the Cytoskeleton.
Cells
March 2025
Renal Division, Department of Medicine IV, Ludwig-Maximilians-University (LMU) Hospital, Ludwig-Maximilians-University (LMU), 80336 Munich, Germany.
A20/Tnfaip3, an early NF-κB response gene and key negative regulator of NF-κB signaling, suppresses proinflammatory responses. Its ubiquitinase and deubiquitinase activities mediate proteasomal degradation within the NF-κB pathway. This study investigated the involvement of A20 signaling alterations in podocytes in the development of kidney injury.
View Article and Find Full Text PDFFebuxostat facilitates neovasculogenesis in chronic kidney disease through xanthine oxidase/NADPH oxidase/c-Jun signaling pathways.
Biomed Pharmacother
March 2025
Department and Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Cardiovascular Research Center, Taipei Medical University Hospital, Taipei, Taiwan; Ph.D. Program of Interdisciplinary Medicine and Biomedical Industry, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address:
The accumulation of uremic toxins in circulation contributes to the cardiovascular diseases that result from chronic kidney disease (CKD). Indoxyl sulfate (IS), which is a protein-bound uremic toxin, promotes cardiovascular diseases with impaired neovascularization by increasing the reactive oxygen species (ROS). This study aimed to investigate febuxostat, a potent xanthine oxidase (XO) inhibitor, for its potential effects on the mechanisms of neovasculogenesis in CKD.
View Article and Find Full Text PDFPredicting Kidney Outcomes in Autosomal Dominant Polycystic Kidney Disease: a Comprehensive Biomarker Analysis.
Clin J Am Soc Nephrol
March 2025
Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Background: Risk stratification tools for Autosomal Dominant Polycystic Kidney Disease (ADPKD) predict kidney outcomes on a group level but lack precision in individuals.
Methods: We assessed the value of adding 13 prognostic biomarkers to established risk factors (sex, age, estimated glomerular filtration rate (eGFR), systolic blood pressure, Mayo Imaging Class (MIC), and mutation type) for predicting disease progression. We included 596 patients from the DIPAK (Developing Intervention strategies to halt Progression of Autosomal Dominant Polycystic Kidney Disease) cohorts with ≥2 eGFR measurements and ≥1 year follow-up.
Canagliflozin Attenuates Podocyte Inflammatory Injury through Suppressing the TXNIP/NLRP3 Signaling Pathway in Diabetic Kidney Disease Mice.
Inflammation
March 2025
Shanghai Putuo Central School of Clinical Medicine, Department of Integrated Traditional Chinese and Western Medicine, Anhui Medical University, Shanghai, 200062, China.
Diabetic kidney disease (DKD), a leading cause of end-stage renal disease (ESRD), poses a serious threat to global health. Aseptic inflammation and pyroptosis of podocytes are crucial factors contributing to the pathogenesis and progression of DKD. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a novel class of antidiabetic agents widely used in clinical settings, may exert a protective effect on podocyte injury, although the underlying mechanisms remain poorly understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!